A novel subcutaneous counterpulsation device: acute hemodynamic efficacy during pharmacologically induced hypertension, hypotension, and heart failure.

摘要

The debut of a new counterpulsation device (CPD) through experimental testing by Bartoli et al. (1) has struck us as very promising. It is our view that the authors have developed a reliable apparatus for providing acute hemodynamic support in various patho-physiologic states. The potential for chronic or acute circulatory support in heart failure conditions with the advantage of diminished invasiveness during implantation may prove very important to improved future treatment. This is especially true for patients on the margin, not yet indicated for a full sternotomy and ventricular assist device insertion but in need of hemodynamic stability. This study builds on this need through an innovative design and device, but questions still remain.